Skip to content

Integrating pharmacists in residential aged care facilities to improve quality use of medicine

Integrating pharmacists in residential aged care facilities to improve quality use of medicine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12620000430932
Acronym
PiRACF study
Enrollment
1668
Registered
2020-04-01
Start date
2020-01-09
Completion date
2022-12-23
Last updated
2022-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will assess the efficacy, cost effectiveness and sustainability of having on-site pharmacist in residential aged care facilities (RACFs), as part of the care team, to improve the quality of use of medicine and reduce hospitalisations among RACF residents. Improved quality use of medication can reduce medication related adverse effects and hospitalisations. The study design is a cluster randomised controlled trial with RACFs in the ACT comparing RACFs with an on-site pharmacist for 2 or 2.5 day a week for 1 year, or usual care (no on-site pharmacist). Findings will inform practice and policy, leading to benefits for RACF residents care, safety and health care budgets.

Interventions

Integrating of on-site pharmacists in residential aged care facilities to improve the quality use of medicine and reduce hospitalisations of residential aged care residents. a) any physical/informational materials used: Pharmacists will be given training in medications management in aged care and study outcomes. They will be provided with a pharmacist tool kit which provides information on study outcomes and relevant guidelines. b) the procedures, activities, and/or processes used: RACFs in t

Integrating of on-site pharmacists in residential aged care facilities to improve the quality use of medicine and reduce hospitalisations of residential aged care residents. a) any physical/informational materials used: Pharmacists will be given training in medications management in aged care and study outcomes. They will be provided with a pharmacist tool kit which provides information on study outcomes and relevant guidelines. b) the procedures, activities, and/or processes used: RACFs in the intervention arm will have a pharmacist integrated into the health care team for 2 or 2.5 days a week (depending on RACF size) for the duration of 12 months. The pharmacist will improve the quality use of medicines through pharmacist activities that are within their current scope of practice as an Australian health professional registered with Australian Health Professional Registered Agency (AHPRA). Pharmacist activities include: • Medication Reviews • Identifying residents at high risk of hospitalisation and prioritising interventions • Vaccination of resident and staff against influenza • Medication reconciliation/review at transition of care • Reviewing and optimising medication rounds • Updating and verifying resident’s clinical information • Answering medication related queries from resident, families and staff • Improving resident’s clinical documentation • Conducting regular clinical audits • Contributing to policies and procedures and education staff about medication management c) what the study involves for participants: RACF residents in the intervention arm will have medication reviews conducted by the pharmacist at transitions of care. This may result in pharmacists discussing medications with residents, and recommendations sent to GPs and other health professionals such as Nurse Practitioners, specialist palliative care, dietitians, and Occupational Therapists. d) the mode of delivery: Face to face. e) the number of times the intervention will be delivered and over what period of time: RACFs in the intervention arm will have a pharmacist integrated into the health care team for 2 or 2.5 days a week (depending on RACF size) for the duration of 12 months f) any strategies used to assess or monitor adherence or fidelity to the intervention (if applicable): The research team will monitor intervention sites for fidelity to the intervention, using two methods informed by Hasson’s Conceptual Framework (2012), that assesses adherence against content, coverage, frequency and duration domains. First, 100% of pharmacist diaries in each intervention RACF will be assessed and cumulative number/proportion of activities will be calculated. Second, a random sample of 10% of intervention RACF medications reviews [of those received a review] will be checked against resident charts by an experienced pharmacist/PI/research team to determine the appropriateness of medications review. Third, interviews with RACF managers/staff and pharmacists will be assessed regarding site buy-in to the model of care, for example, engagement in conducting trial activities. Sites will be given a fidelity rating of high/medium/low based on the assessment.

Sponsors

University of Canberra
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Inclusion criteria for residential aged care facilities: - An accredited facility - Located in the ACT - More than 20 beds Inclusion criteria for residential aged care residents: - Permanent resident in a facility that fits inclusion criteria

Exclusion criteria

Respite residential aged care facility residents will be excluded. Existing government funded Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) services conducted by pharmacists visiting residents in aged care facilities are excluded from intervention (on site pharmacist) activities.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 22, 2026